Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 10 Gastro-enteropancreatic neuroendocrine tumor 4 Pheochromocytoma 2 Paraganglioma 2 Vipoma 1 Thymus Neoplasms 1 Rhabdomyosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Meningioma 1 Lymphoma 1 Insulinoma 1 Gastrinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Merkel Cell 1 Carcinoid Tumor 1

Interventions

Magnetic Resonance Spectroscopy 16 Hydroxyurea 7 Everolimus 7 Bevacizumab 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 6 Radiosurgery 6 Proton Therapy 6 Specimen Handling 5 pembrolizumab 4 Surveys and Questionnaires 4 Surgical Procedures, Operative 4 Radiotherapy 4 Imatinib Mesylate 4 Cyclophosphamide 4 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4 aldesleukin 3 abemaciclib 3 Tranexamic Acid 3 Temozolomide 3 Sunitinib 3 Sodium Chloride 3 Radiotherapy, Intensity-Modulated 3 Observation 3 Nivolumab 3 Ga(III)-DOTATOC 3 90Y-octreotide, DOTA-Tyr(3)- 3 vistusertib 2 trametinib 2 ribociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all

NCT04997317 2025-04-13

PROMENADE

University Hospital, Basel, Switzerland

Phase 1/2 Recruiting

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡